Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Iron Dextran→

Iron Dextran Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
9004-66-4
Molecular formula
Not available
Molecular weight
Not available
Drug class
Intravenous iron(III)-dextran complexparenteral iron replacement agent
Mechanism of action
A colloidal iron(III)-hydroxide core complexed with dextran. After administration, iron is taken up by reticuloendothelial cells and released for transferrin binding and incorporation into haemoglobin and iron stores; it is not a simple dissociating iron salt.
Indications / reported uses
  • Treatment of documented iron deficiency in adults and paediatric patients aged 4 months and older who cannot tolerate oral iron or have had an unsatisfactory response to oral iron; formulation-specific test-dose and hypersensitivity precautions apply

Sources: US DailyMed — INFeD (iron dextran) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Iron Dextran Environmental Risk Assessment (ERA) (the Iron Dextran ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.